This year marks the Company’s 30th anniversary in China and its eighth year at the China International Import Expo (CIIE). Held from Nov. 5-10, the prestigious event is regarded by global healthcare companies to be a vital platform for showcasing technology-driven innovations and expanding local partnerships.
This year's event featured 4,108 companies from 138 distinct countries, occupying over 367,000 square meters of exhibition space, and introducing 461 new products, technologies, and services. EssilorLuxottica showcased AI-driven vision solutions and strengthened partnerships with leading Chinese institutions dedicated to visual health. A highlight was the Group’s expanded myopia management platform, enhancing its commitment to address myopia in the projected 740 million children worldwide by 20501 through innovative solutions.
Pioneering Myopia Management Solutions
A standout moment at CIIE was when the Group showcased how it expanded its myopia management platform with the new Essilor Stellest 2.0 lenses powered by H.A.L.T.* MAX technology that deliver significantly higher efficacy in slowing myopic eye growth.1,2 ; The platform also includes Essilor Stellest plano pair lenses for early intervention; designed to help delay the onset of myopia2,3 and Essilor Stellest Smartglasses, developed to provide behavioral insights and help respect support consistent wearing compliance.4 Marking an important milestone in the industry, Essilor Stellest lenses are now recognized as the first and only FDA market authorized spectacle lens in the United States 5,6. They provide eyecare professionals with a clinically validated, non-invasive option that can help slow myopia progression in children. The impactful announcement on FDA market-authorization followed the unveiling of new six-year clinical data reinforcing the long-term efficacy of Essilor Stellest lenses in managing myopia progression and axial elongation in children and young adults.7 The results underscore the significant and sustained impact of Essilor Stellest lenses in controlling myopia progression, offering valuable insights into strategies for addressing the global myopia epidemic.
Strategic Partnerships with Leading Institutions
The Group’s participation at the CIIE also highlighted significant partnerships with leading academic institutions and health organizations. In collaboration the China Center for Health Development Research at Peking University, EssilorLuxottica launched the National Visual Health Report 2.0, aimed at enhancing eye health awareness and practices across all life stages.
In a joint effort with the Shanghai Eye Disease Prevention and Treatment Center, the Company rolled out Guidelines for Graded and Classified Intervention of Myopia. These guidelines provide essential, evidence-based strategies for managing myopia prevention among children and adolescents, demonstrating EssilorLuxottica’sproactive stance on national visual health challenges.
Innovative Solutions for Enhanced Healthcare
EssilorLuxottica continues to lead the industry with groundbreaking innovations. The Nuance Audio Hearing Glasses, a first for the Chinese market, offer individuals with mild to moderate hearing loss an alternative to traditional hearing aids, removing psychological barriers. Additionally, the instrument ARK 500NV Accommodation Response Tester improves eye care with comprehensive testing features for personalized near-vision fatigue management, enhancing comfort and clarity. It evaluates accommodation response, lens opacity, and objective refraction, supporting tailored plans for greater comfort and visual clarity for adults.
Continuing to Drive Impact
The OneSight EssilorLuxottica Foundation unveiled a strategic partnership with the China Rural Development Foundation, celebrating ten years of impactful optical philanthropy and setting the foundation for future initiatives. This partnership underscores the Company’s long-standing commitment to visual health in China and highlights a future oriented towards innovation and collaboration.
EssilorLuxottica’s participation in CIIE 2025 not only reaffirms its industry leadership but also showcases its vision for transforming and empowering individuals with advanced solutions tailored to consumer needs. As it celebrates three decades in China, the Company remains dedicated to driving progress and innovation in visual health, setting new standards for excellence in the industry.
Notes:
1. Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036-1042. doi:10.1016/j.ophtha.2016.01.006
2 Based on 12-month results from a prospective, randomized, double-masked contralateral crossover clinical trial conducted in Singapore on 50 children. EssilorLuxottica data on file (2025).
3. Twice the power refers to two (or more) times the depth of volume of non-focused light (by design) compared to that of Essilor Stellest lenses—and is not associated with a doubling of lens power, lenslet power, or efficacy.
4 Compared to single vision lenses. Results from a prospective, randomized, double-masked, multicenter U.S. clinical trial in myopic children aged 6–12 years at initiation of treatment.
5 Essilor Stellest 2.0 and Essilor Stellest plano pair (for pre-myopia) are not currently available in the U.S.
6 Zhang Z, Zeng L, Gu D, Wang B, Kang P, Watt K, Zhou J, Zhou X, Chen Z, Yang D, Chen C, Wang X, Zhou X, Chen Z. Spectacle Lenses With Highly Aspherical Lenslets for Slowing Axial Elongation and Refractive Change in Low-Hyperopic Chinese Children: A Randomized Controlled Trial. Am J Ophthalmol. 2025 Jan; 269:60-68. doi: 10.1016/j.ajo.2024.08.020. Epub 2024 Aug 27. PMID: 39197509.
7 Bullimore MA, Brennan NA. Myopia: An ounce of prevention is worth a pound of cure. Ophthalmic Physiol Opt. 2023 Jan;43(1):116-121. doi: 10.1111/opo.13058. Epub 2022 Oct 5. PMID: 36197452.
